Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma
- PMID: 28841699
- PMCID: PMC5571912
- DOI: 10.1371/journal.pone.0183816
Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma
Abstract
Background: Primary vaginal carcinoma (PVC) is a rare malignancy. Established prognostic factors include tumour stage and age at diagnosis. The leucine-rich repeats and immunoglobuline-like domains (LRIG)-1 protein functions as a tumour suppressor, but less is known about the functions of LRIG2 and LRIG3. The present study aimed to evaluate the expression of LRIG proteins and analyse their possible associations with clinical characteristics and survival in a cohort of PVC patients.
Methods: We used immunohistochemistry to investigate LRIG1, LRIG2, and LRIG3 expression in tumour samples from a consecutive cohort of 70 PVC patients. The association between LRIG protein expression and clinical characteristics and cancer-specific survival was investigated using univariate and multivariate analyses.
Results: The majority of PVC patients (72%) had >50% LRIG1- and LRIG2-positive cells, and no or low LRIG3-positive cells. HPV status was significantly correlated with LRIG1 expression (p = 0.0047). Having high LRIG1 expression was significantly correlated with superior cancer-specific survival in univariate and multivariate analyses. LRIG2 and LRIG3 expression did not significantly correlate with clinical characteristics or survival.
Conclusion: LRIG1 expression might be of interest as a prognostic marker in PVC patients, whereas the role of LRIG2 and LRIG3 expression remains to be clarified.
Conflict of interest statement
Figures
Similar articles
-
Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma.Int J Oncol. 2013 Jan;42(1):247-52. doi: 10.3892/ijo.2012.1702. Epub 2012 Nov 16. Int J Oncol. 2013. PMID: 23165628
-
LRIG and cancer prognosis.Acta Oncol. 2014 Sep;53(9):1135-42. doi: 10.3109/0284186X.2014.953258. Epub 2014 Sep 2. Acta Oncol. 2014. PMID: 25180912 Free PMC article. Review.
-
LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.Lung Cancer. 2018 Nov;125:174-184. doi: 10.1016/j.lungcan.2018.09.017. Epub 2018 Sep 24. Lung Cancer. 2018. PMID: 30429017
-
Immunohistochemical analysis of LRIG proteins in meningiomas: correlation between estrogen receptor status and LRIG expression.J Neurooncol. 2012 Jul;108(3):435-41. doi: 10.1007/s11060-012-0856-x. Epub 2012 Apr 8. J Neurooncol. 2012. PMID: 22484910
-
The LRIG family: enigmatic regulators of growth factor receptor signaling.Endocr Relat Cancer. 2014;21(6):R431-43. doi: 10.1530/ERC-14-0179. Epub 2014 Sep 2. Endocr Relat Cancer. 2014. PMID: 25183430 Free PMC article. Review.
Cited by
-
LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.Int J Oncol. 2018 Sep;53(3):1069-1082. doi: 10.3892/ijo.2018.4482. Epub 2018 Jul 16. Int J Oncol. 2018. PMID: 30015847 Free PMC article.
-
The Prognostic and Therapeutic Potential of LRIG3 and Soluble LRIG3 in Glioblastoma.Front Oncol. 2019 Jun 6;9:447. doi: 10.3389/fonc.2019.00447. eCollection 2019. Front Oncol. 2019. PMID: 31245283 Free PMC article.
-
LRIG1‑2 and LMO7 immunoreactivity in vulvar squamous cell carcinoma: Association with prognosis in relation to HPV‑DNA and p16INK4a status.Oncol Rep. 2019 Jul;42(1):142-150. doi: 10.3892/or.2019.7138. Epub 2019 May 2. Oncol Rep. 2019. PMID: 31059071 Free PMC article.
-
LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.Biosci Rep. 2019 Jan 8;39(1):BSR20181165. doi: 10.1042/BSR20181165. Print 2019 Jan 31. Biosci Rep. 2019. PMID: 30487162 Free PMC article.
-
Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis.J Cancer. 2018 Jul 30;9(16):2895-2909. doi: 10.7150/jca.24749. eCollection 2018. J Cancer. 2018. PMID: 30123358 Free PMC article.
References
-
- Beller U, Benedet JL, Creasman WT, Ngan HY, Quinn MA, Maisonneuve P, et al. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1: S29–S42. - PubMed
-
- Gunderson CC, Nugent EK, Yunker AC, Rocconi RP, Graybill WS, Erickson BK, et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. J Low Genit Tract Dis 2013;17: 409–413. doi: 10.1097/LGT.0b013e3182800ee2 - DOI - PubMed
-
- Hellman K, Silfversward C, Nilsson B, Hellstrom AC, Frankendal B, Pettersson F. Primary carcinoma of the vagina: factors influencing the age at diagnosis. The Radiumhemmet series 1956–96. Int J Gynecol Cancer 2004;14: 491–501. doi: 10.1111/j.1048-891x.2004.014310.x - DOI - PubMed
-
- Orton A, Boothe D, Williams N, Buchmiller T, Huang YJ, Suneja G, et al. Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol 2016;141: 501–506 doi: 10.1016/j.ygyno.2016.03.011 - DOI - PubMed
-
- Hacker NF, Eifel PJ, van der Velden J. Cancer of the vagina. Int J Gynaecol Obstet 2015;131 Suppl 2: S84–S87. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous